A structure-guided enzyme engineering platform that modifies plant GH3 acyl acid amido synthetases to conjugate and inactivate the widely used herbicide 2,4-D. Leveraging characterized activity of AtGH3.15 with the related herbicide 2,4-DB, this approach aims to develop novel biocatalysts for herbicide detoxification, with applications in agriculture, environmental remediation, and crop protection.
This research program focuses on engineering GH3 acyl acid amido synthetases—enzymes naturally found in plants—to inactivate the broadleaf herbicide 2,4-D (2,4-dichlorophenoxyacetic acid) through amino acid conjugation. The team has demonstrated that the Arabidopsis enzyme AtGH3.15 catalyzes the rapid conjugation of amino acids to the structurally related herbicide 2,4-DB, representing the first known GH3 protein with activity toward a synthetic herbicide. Using structural insights from X-ray crystallography, the project aims to redesign enzyme active sites to shift substrate preference toward 2,4-D, enabling new approaches to herbicide management, crop selectivity, and environmental bioremediation.
Core technology:
Key findings to date:
The program is at an early-to-mid stage of development. Published biochemical and structural characterization of AtGH3.15 has established proof-of-concept for GH3-mediated herbicide conjugation. Current work focuses on active-site mutagenesis to redirect activity toward 2,4-D, followed by mutant library screening and activity validation. Downstream applications in transgenic crop engineering, herbicide selectivity, or bioremediation would require additional development beyond the current enzyme engineering phase.
Washington University in St. Louis is a private research university with a large graduate and professional footprint and a major clinical enterprise. Its medical campus is integrated with a leading hospital system, enabling joint clinical research, secure data access, and large-scale trial recruitment. An adjacent innovation district and partner incubators provide flexible lab space, prototyping resources, and corporate co-location, while shared core facilities welcome external users under service agreements. Research is supported by NIH, NSF, DOE, and other competitive federal funding alongside industry sponsorship. A dedicated technology transfer office manages IP, licensing, startup formation, and streamlined sponsored research and clinical trial agreements.